The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Summary: Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side eff...
Guardado en:
Autores principales: | Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, Aurélie Bouteau, Henri Estanbouli, Botond Z. Igyártó |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8c4e06d68ede410195a0440cfbbaaac1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
por: Marco Maugeri, et al.
Publicado: (2019) -
Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
por: Kirill V. Kalnin, et al.
Publicado: (2021) -
Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform
por: Samuel V. Rasmussen, et al.
Publicado: (2021) -
Anti-Inflammatory Activity of Bullfrog Oil Polymeric Nanocapsules: From the Design to Preclinical Trials
por: Amaral-Machado L, et al.
Publicado: (2021) -
Lipid rafts: cell surface platforms for T cell signaling
por: MAGEE,TONY, et al.
Publicado: (2002)